The company will announce the new suite during the BIO International Convention this week in Philadelphia, PA.
According to Catalent, OneBio was designed to address biologic development challenges by providing customers with a single contract, program manager, and development timeline.
“In OneBio, Catalent offers its partners the improved communications associated with streamlined program management and a single point of contact, reduced timelines brought about through parallel processing, and the increased flexibility of a global network of expertise and resources,” a Catalent spokesperson told us.
In early April, Catalent invested $5m in a new drug development center of excellence to expand its hot melt extrusion (HME) capabilities for formulation and drug delivery method optimization.
According to the company, the expansion enables Catalent to develop amorphous dispersions and controlled and modified drug delivery, such as controlled release for enhanced bioavailability.
Catalent also last month announced that it is installing new equipment to increase its formulation capabilities and capacity to manufacture controlled-release tablets and capsules.
The $40m investment will see the addition of a laser drill for osmotic drug delivery and stick pack dosage manufacturing capabilities at the company’s Winchester, KY-based facility.